Mark Chao, TenSixteen CEO
With Forty Seven co-founder at the helm, new biotech spinout launches to target mutations potentially linked to numerous diseases
Mark Chao is going back into biotech — and his new company, launched this morning, is going after mysterious mutations in the blood and how they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
